As far as T-cell proliferation is concerned, we observed that the different extracts of Zizyphus lotus L. (Desf).
In about one-third of glioma patients, Ueda et al (2004) could detect anti-SOX6 antibodies but so far, no T-cell epitope was described.
Unlike solid tumors, the mutation frequencies in AXIN1, APC and CTNNB1 genes together accounted for only ∼5% of the T-ALL patients, and this gives the idea that the contribution of these mutations far exceeded T-cell leukemogenesis.
So far, large-scale T-cell repertoire analysis has been limited to interrogation of a single TCR subunit per sequencing run.
So far tumour-specific T-cell receptors have been used only for diseases other than melanoma; for example, a high-affinity CD19 binding antibody has been used successfully in B-cell lymphomas/leukaemia [69 71].
Thus far, the CD8+ T-cell response of the remaining individuals has been anecdotally reported and not well characterized (Hersperger et al., 2010, Lecuroux et al., 2014, Migueles et al., 2002, Migueles et al., 2008, Migueles et al., 2009, Saez-Cirion et al., 2007, Saez-Cirion et al., 2009).
In addition to this increase of KLRG1+ Treg cells, we found far less advantageous effector T-cell to MDSC ratios in the tumors of mice treated with GVAX as opposed to FVAX (Figure 8).
Alternatively, reports thus far describing modulation of T-cell activity have used PBMCs and lymph node cells, whereas our present studies used purified T cells, which appear relatively insensitive to VIP.
So far, the strategies used to examine T-cell recognition have been based largely on mapping T-cell epitopes with overlapping peptides from known proteins or with entire proteins, e.g., from a specific virus, bacterium, or human tissue.
Overall, the performance of the methods is still far from the quality achievable in T-cell epitope prediction.
These data may correlate with a generally higher incidence of T-cell lymphomas in Far Eastern regions [ 16].
